matched controls (n= 16) and analyzed whether a protein-based (tetanus-diphtheria toxoid)
or a carbohydrate (Pneumovax) moiety will result in an improved immunological response.
Results: An appropriate serological response in IgG titers for diphtheria was seen in 40% of
patients on ibrutinib and 31% of patients in the control group. About 30% of patients on
ibrutinib and 44% of patients in the control group had an adequate response to tetanus …